2025 Tandem Meetings Posts
Deeper MRD response associated with better survival in obe-cel-treated patients with B-cell ALL
Measurable residual disease (MRD) negativity was associated with better response to treatment with the chimeric antigen receptor T-cell therapy obecabtagene autoleucel (obe-cel) in patients with B-cell acute lymphoblastic leukemia (ALL). […]
Earlier administration of CAR-T treatment may improve survival in LBCL
Axicabtagene ciloleucel (axi-cel) prolonged survival in large B-cell lymphoma (LBCL) compared with standard of care (SOC), and the ZUMA-7 trial also found that survival outcomes may differ in those with […]
Hematologic cancer survivors show accelerated brain aging
Survivors of hematologic cancers might experience worse neurocognitive functioning compared with their healthy counterparts, according to an abstract presented at the 2025 Transportation and Cellular Therapy Tandem Meetings of ASTCT […]
Study questions clinical benefit of dexamethasone with axi-cel in LBCL patients
Prophylactic dexamethasone did not improve the safety or efficacy of axicabtagene ciloleucel (axi-cel) in patients with large B-cell lymphoma (LBCL), according to a study presented at the 2025 Transportation and […]
ACROBAT interim results support AlloHeme for relapse prediction in AML, MDS
Interim results of the ACROBAT study suggest that increasing microchimerism and loss of complete chimerism may indicate relapse risk in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). […]
